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INTRODUCTION

CCAA T/enhancer binding proteins (C/EBP)
The transcription factor CCAAT/enhancer binding proteins(C/EBP) are expressed
at high levels in tissues which play a central role in energy metabolism, such as adipose

and liver. They are known to play a critical role in normal cellular differentiation and
metabolic function in a variety or organs, such as adipose tissue, placenta, liver, lung,

kidney, small intestine, brain, and hematopoietic cells [ 1 ]. C/EBPs are basic leucine
zipper (bZIP) transcription factors. They have a stretch of basic amino acids within the
carboxyl-terminal DNA binding domain and a dimerization domain where 7 leucine
repeats occur within a 35-amino-acid sequence. The C/EBPs comprise a sub-family of

homologous transcription factors. There are currently six members of the C/EBP family
designated as C/EBPa, [, 5, /,

, and

[2]. C/EBP proteins function by forming

homodimers or heterodimers with one another or with other bZIP family members.
Dimerization is necessary for DNA binding and transcriptional activation.

C/EBP

mRNA has multiple in-frame AUGs which initiate translation of full length or aminotruncated isoforms (Fig. 1). The larger product, originally called LAP (liver-enriched
activator protein), comains the N-terminal transactivation domains and functions as a

transcriptional activator. The smaller product, p20C/EBP[ (originally called LIP),
contains the C-terminal bZIP domain but lacks the N-terminal trans-activation domain,

and therefore acts as a dominant negative regulator of C/EBP function [3]. It has recently
been reported that in prenatal and newborn liver, the p20C/EBPI3 isoform

cm arise by a

second mechanism, a specific proteolytic cleavage of full-length C/EBP[3 tliat is

C/EBPc-dependent [4].
C/EBPs are synthesized by cells throughout the body as well as by osteoblasts,

and are now known to regulate a diverse list of target genes. It has been established,

using pluripotent and preadipocytic cell lines, that C/EBPs regulate adipocyte

commitment, differentiation, and gene expression. Their vital roles in adipocyte
differentiation have been widely studied, and clearly demonstrated by disruption of the

C/EBPcz,[5] C/EBP, and C/EBP6 genes [6], which prevented the normal development
of adipose tissue. Some studies suggested that C/EBP[3 and C/EBP6 play an early role in
the differentiation pathway, regulating commitment of multipotential mesenchymal

precursor cells into preadipocytes, and leading to the activation of the gene encoding
C/EBPoc [7,

8]. Therefore, preadipocytes express high level of C/EBP/6, and

subsequently induce expression of C/EBPa and PPAR3,, which in ram, direct expression
of terminal adipocyte marker genes [9-11 ].

Although the important roles of C/EBP transcription factors in promoting
adipogenesis have been well described, very little is known about their poss..ible role in
osteogenesis. Cumulative evidence indicates that osteoblasts and adipocytes share a
common pluripotent progenitor in the bone marrow. Bone marrow stromal cells placed

under appropriate culture conditions can be differentiated into the osteoblast or adipocyte

lineage [ 12-14]. They are thought to be multipotent mesenchymal stem cells, as opposed
to mixtures-of committed progenitor cells, each with restricted potential [ 14]. It was

reported that induction of adipogenesis in murine BMS2 cells was accompanied by a
decrease in expression of osteoblastic marker genes, including alkaline phosphatase (AP),

Collal, and BSP [15]. Conversely, the osteoinductive hormone BMP-2 was shown to
inhibit adipogenesis [ 16]. Some demonstrated the extent of plasticity between the
differentiation of adipocytic and osteogenic cells in human bone marrow stromal cell

cultures [ 17]. However, it remains unknown whether de-differentiation of committed
cells to a pluripotem state or trans-differentiation between the osteoblast ant adipocyte

lineages can occur in vivo.

A number of studies have identified C/EBP regulation of genes expressed in
osteoblasts. Insulin-like growth factors (IGFs) I and II are the growth factors secreted by

skeletal cells and are considered autocrine regulators of osteoblastic cell function [18,

19]. They have mitogenic activity for bone cells and enhance the differentiated function
of the osteoblast [20, 21 ]. It was reported that C/EBP6 enhances either basal or

prostaglandin E2-activated transcription of the IGF-I promoter in osteoblasts [22, 23], and
that expression of the cl subunit of type I collagen [24, 25] and COX-2

[2d] in

osteoblasts is regulated by C/EBP factors. Recently it was found that C/EBP and Runx2
factors interact together in a synergistic manner to enhance the bone-specific osteocalcin

(OC) gene up to 40-fold in cell culture system, suggesting that this imeraction is a
principal mechanism for regulating tissue-specific expression during osteoblast
differentiation [27]. Runx2 is known to play an essemial role in osteoblast differentiation

by stimulating transcription of osteoblast-related genes, including OC, type I Collagen,
and osteopomin (OP) [28, 29].

Osteoblast

The osteoblast is derived from a mesenchymal origin, and is known to produce
most of the bone extracellular matrix (ECM) proteins, such as type I collagen, alkaline

phosphatase, OC, BSP, and OP, when they are terminally differentiated. Osteoblasts are
also responsible for the mineralization of this ECM. Based on bone nodule formation in

vitro, the osteoblast development process can be subdivided into three stages" 1)
proliferation, 2) extracellular matrix development and maturation, and 3) mineralization.

Expression of osteoblast marker genes are acquired or lost as the progenitor cells
differentiate and matrix matures and mineralizes. In general, alkaline phosphatase
increases early in the differentiation program then decreases when mineralization is well

progressed; OP peaks twice, during proliferation and then again later but prior to certain
other matrix proteins including BSP and OC; BSP is transiently expressed very early and
then upregulated again in differentiated osteoblasts forming bone; and OC appears at the
time of mineralization [30]. All osteoblast marker genes seem to be upregulated prior to

cessation of proliferation in precursors except OC, which is upregulated only in post-

proliferative osteoblasts [31 ]. Type I collagen, another known osteoblast arker, is also

upregulated in committed osteoprogenitor cells. The deposition of type I collagen seems
to be a relatively early event in the osteoblast differentiation pathway. Collagen matrix

synthesis and deposition, which are induced by ascorbic acid, appears to be essential for
the expression of early osteoblast markers, and ultimately induction of OC [32, 33].

Bone Marrow Stromal Cells
Marrow stromal populations are known to comain cells that support
hematopoiesis, as well as the mesenchymal stem cells and their progeny, including
connective tissue cells such as osteoblasts, chondrocytes, tenocytes, adipocytes, and

smooth muscle cells [34]. When the term "stromal cells" is used, it refers loosely to the

nonhematopoietic cells of mesenchymal origin. Committed osteoprogenitors that are
restricted to osteoblast development and bone formation can be idemified by functional

assays of their differentiation capacity to form bone nodules in vitro. In vivo, osteogenic

precursors can be identified by morphologic and immunohistochemical methods, and in
vitro, the stromal cells can be separated from hematopoietic cells by their differential
adhesion to tissue culture plastic and their prolonged proliferative potential. Osteoblastic

cells in vivo are categorized in a presumed linear sequence progressing from

osteoprogenitor to preosteoblasts, osteoblasts, and then osteocytes. These earlier

morphological definitions are supplemented by elucidation of cell and tissue specific
macromolecules including the bone matrix molecules (type I collagen, OC, OP, BSP) and
transcription factors that regulate them and commitment/differentiation evems (AP-1,
Msx-2, Cbfa-1, and possibly C/EBP).

Bone Morphogenetic Proteins (BMPs)

Bone morphogenetic proteins (BMPs) belong to the TGF-beta supefamily and
are characterized by their ability to induce ectopic bone formation [35]. They induce the

differentiation of mesenchymal progenitor cells to chondrocytes. They then produce

cartilage, which is later replaced by bone [36]. The application of BMPs fo.r bone defects
and to augment bone has been studied extensively in the fields of orthopedics and

dentistry. The therapeutic use of recombinant BMPs, such as recombinant human (rh)

BMP-2, in the treatment of periodontal disease has drawn a great interest due to their
potent ability to stimulate intramembranous bone formation without an endochondral
imermediate [37].
Rationale

FLAG-tagged p20C/EBP[ transgenic mice, which were created in our laboratory,
overexpress a transcriptionally inactive dominant negative form of C/EBP[, and
therefore should decrease activity of all C/EBPs. In our preliminary studies, in which we
utilized four lines of these transgenic mice, it was found that three of four lines exhibited

osteopenia, possibly due to impaired osteoblast differentiation or function. These mice,
in which the 3.6 kb Collal promoter/first intron directs expression of a p20C/EBP[

transgene to bone, show decreased trabecular bone volume and cortical thickness.

Dynamic histomorphometry showed a decrease in the mineral apposition and bone
formation rates, consistent with an inhibition of bone formation in this model. Long

bones and calvariae of transgenic mice showed reduced Collal and OC mRNA levels in
vivo. In addition to osteopenia, transgenic mice showed increased pre- or peri-natal

lethality, reduced body weight, decreased extra-medullary white fat and democraniofacial abnormalities, including malocclusion of incisors. Based on the pattern of

transgene expression in the original four lines, these features appear to be the effect of

FL-p20C/EBP[ overexpression.

To test the hypothesis that p20C/EBP[ inhibits osteoblast differemiation, we used
an ex vivo bone marrow stromal cell culture model. In some experiments, heterozygous

p20C/EBP[ mice were crossed with a homozygous pOBCol2.3-GFP mouse so that all
progeny were heterozygous for the GFP transgene, an established marker of the
differentiated osteoblast. Osteoblast differentiation was assessed by the formation of
mineralized bone nodules and the expression of osteoblast markers such as CollA1, BSP,

GFP, OP, and OC. This study was the first step toward elucidating the role of C/EBP
transcription factors, in the control of osteoblast differentiation and bone mass. We
hypothesize that targeted expression of p20C/EBP[3 inhibits osteoblast differemiation in
transgenic mice leading to osteopenia.

MATERIAL AND METHODS

Creation

of FLA G-tagged p20C/EBP transgenic mice

Preparation ofFLAG-taggedp2OC/EBP" In order to identify cells that express

the C/EBP transgene, we incorporated an amino-terminal FLAG epitope into the

p20C/EBP[ construct. Therefore, cells that express the C/EBP transgene will also
necessarily express the FLAG protein, which can be identified by Western blotting,

EMSA supershifting, and immunocytochemistry using the M2 FLAG antibody (Kodak).
This will allow us to easily differentiate our expressed transgenic p20C/EBP from

endogenous, naturally occurring C/EBP isoforms. The inclusion of the FLAG epitope
does not interfere with the dominant negative function of p20C/EBP because of the
modular nature of transcription factors. The FLAG p20C/EBP[ construct was prepared

by PCR using the original CMV-LIP plasmid as a template. A primer pair that spans the
entire p20C/EBP plus the FLAG epitope was utilized, creating a product 467bp in size.

Following PCR amplication with Taq polymerase, the product was unidirectionally
cloned into pCR3.1-Uni, a TA expression vector containing the CMV promoter for
mammalian expression and a T7 RNA polymerase site for in vitro translation. The

predicted FLAG p20C/EBP[ construct was confirmed by sequencing.

A series of experiments were performed to confirm that the FLAG-tagged
p20C/EBP[3 exhibits the expected DNA binding, nuclear localization, and dominantnegative function.

Targeting ofFLp2OC/EBPfl to Osteoblastic Cells: A pOBCol3.6-FLp20C/EBPI3
construct was used to target expression of FLp20C/EBP broadly throughout the

osteoblast lineage. PCR3.1-FLp20C/EBP[ was digested with HindIII and XbaI and the
resulting FLp20C/EBP fragment was subcloned into an intermediate Cla ector which
contains a polylinker and the bovine growth hormone (bGH) polyadenylation sequence

flanked by two ClaI sites. Following ClaI digestion, the FLp20C/EBP-bGH cassette

(792 bp) was isolated and subcloned into pBCSK+ColInt5.2Xba, which contains a ClaI
site downstream of the 3.6 kb Collal promoter and 1.6 kb Collal first intron. Clones

containing FLp20C/EBP in the correct orientation were identified using asymmetric
restriction sites. The pOBCo12.3-FLp20C/EBP[ construct, which will target expression
to more differentiated osteoblasts, will be prepared by subcloning the ClaI

FLp20C/EBP-bGH cassette into an expression vector which is identical e:cept that the
Collal promoter has been 5’ truncated to 2.3 kb.

Due to the fact that there is differential utilization of Col 1 al promoter elements as
cells progress through the lineage, it is possible to target expression of FLp20C/EBP[ to
cells at multiple stages of the osteoblast lineage. Therefore, FLp20C/EBP with a

pOBCol3.6 construct, instead of pOBCol2.3 construct, was used since it was reported
that pOBCol3.6GFP is an early marker of the osteoblast lineage being expressed in early

pluripotent progenitor cells while pOBCol2.3GFP expression is restricted to more
differentiated osteoblasts [38].
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Preparation of Transgenic FL p2OC/EBPfl Overexpressing Mice Transgenic
CD-1 mice overexpressing FL p20C/EBP were prepared by pronuclear microinjection

of pOBCo13.6-FL p20C/EBP. Potential founders were screened by dot blot analysis of
tail snip DNA using a probe directed against the human growth hormone polyadenylation

site, which is cloned downstream of p20C/EBP. Mice that screened positive for the
human growth hormone 3’-UTR were confirmed by PCR using a 5’-primer directed

against the Collal first intron (5’-ACCCTCCTCCATTTTAGCC-3’) and a 3’-primer
directed against the FLAG epitope (5’-CATCGTCGTCCTTGTAGTC-3’). Four

transgenic founders (2 male, 2 female) were obtained and bred with wild type CD-1 mice
to establish transgenic lines. Progeny are screened for the presence of the transgene at

the time of weaning by tail snip, DNA extraction, and PCR.

Bone marrow stromal cell cultures

Heterozygous pOBCol3.6-FLp20C/EBP transgenic mice were crossed with
homozygous pOBCol2.3GFP reporter mice so that all progeny were heterozygous for the

GFP transgene. Both male and female mice were used, with the sex ratio held constant
for wild-type and transgenic groups. Femurs and tibiae were dissected out from the 6-

week-old wild type and transgenic mice. Adherent tissue was cleaned, and then the

epiphyses were cut to expose the marrow cavity. Bone marrow was flushed into sterile

robes containing alpha-minimum essential medium. (c-MEM) with 10% heat-inactivated
fetal calf serum (FCS), streptomycin (50tg/ml), and penicillin (100tg/ml). Bone marrow
was then pooled and passed through a nylon filter to create a single cell suspension.
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Cells were coumed with a Coulter counter and plated in 35mm wells of 6-well plates at a

density of 400,000/sq.cm. On the third day, half of the medium was replaced with fresh
medium containing 10% FCS. On day 7, fresh medium supplemented with 50tg/ml

ascorbic acid and 8mM 3-glycerolphosphate was added to cultures. Cultures were then

fed with fresh medium every other day up to 21 days. In some experiments, cultures
were maintained up to 28 days. In some studies, 30 ng/ml of BMP-2 was added to

cultures as an osteogenic stimulus. The osteogenic capacity of bone marrow stromal cell

cultures were assessed by Northern blot analysis for osteoblast marker gene expression,
visualization of GFP fluorescent colonies by fluoroimager and fluorescence microscopy,
and alkaline phosphatase staining and activity,

Northern Blot Analysis

RNA extracts were obtained from cultured bone marrow stromal cetls on day 10,
14, 17, 21, and in some experiments, on day 28. RNA was prepared from cultured cells
using TRIzol Reagent according to the manufacturer’s instructions. After the isopropanol

precipitation, the pellet was redissolved in 300 tl of GTC buffer (4.5 M of guanidinium
isothiocyanate, 10 mM of 2-mercaptoethanol ([-MSH), 15 mM of sodium N-lauryl
sarcosine, and l 0mM of sodium citrate, pH 7.0) followed by precipitation with 300 tl

isopropanol. The precipitate was washed once with 80% ethanol, drained, and
redissolved in 50

tl of water. RNA was separated on a 2.2 M formaldehyde/1% agarose

gel and transferred onto Genescreen (New England Nuclear, Boston, MA, iJSA) by
positive pressure. Membranes were probed with a 900-base pair(bp) PstI fragment of rat
Collal (pclR2)[39], a 440-bp PstI/EcoRI mouse OC fragment (p923)[40], and a 1000-

12

bp EcoRI mouse BSP and OP fragmem [41]. Probes were radiolabeled by the random
primer method using (ct-32p)deoxycytosine triphosphate (dCTP; 3000 Ci/mmol; New

England Nuclear, Boston, MA, USA) obtaining a probe-specific activity of
approximately 1 x 10 9 cpm/gg. Filters were hybridized with 3 x

106 cpm/ml a2p-labeled

probe at 42C in in 50% formamide, 5x SSPE (lx SSPE 0.149 M of NaC1, 10 mM of
NaH2PO4, and 1 mM of EDTA, pH 7.4), 1.2 x Denhardt’s solution, and 0.5% sodium

dodecyl sulfate (SDS)[42]. Filters were washed once in 6x SSPE and 0.5% SDS for 10
minutes at room temperature, once in 0.1 x SSPE and 0.1% SDS for 10 minutes at 65C.

Prior hybridization signals were removed by washing in 0.1 x SSPE and 0.1% SDS for

20-30 minutes at 80C. Filters were exposed to X-ray film with an intensifying screen at

-70C.

Imaging of mineralized colonies and GFPfluorescent colonies

GFP fluorescem colonies were imaged on days 7, 10, 14, 17, 21, and in some
experiments on day 28 in living cells at the macroscopic level using a fluorimager and at
the cellular level by fluorescence microscopy.

Fluorescent and brightfield microscopy" GFP expression in cell culture was
visualized using an Olympus IX50 inverted system microscope equipped with an IX-FLA

inverted reflected light fluorescence (Olympus America, Inc., Melville, NY, USA).

Fluorescent images were viewed using GFPtpz filters (exciter, D500/20; dichroic,

525DCLP; emitter, D550/40) with equal exposure times. The images were recorded with
a SPOT-camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA). 100x
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magnification was used. In order to obtain a fluorescent image of the entire well, 25
contiguous and adjacent images arrayed in a 5 x 5 configuration were obtained at 10X

magnification using a fluorescent microscope equipped with a computer controlled
motorized stage. These images were then concatenated to form a single high-resolution

image covering approximately 60% of a 35 mm well. The images of mineralized
colonies under transmitted light were taken with the same equipment.

Fluorimager analysis GFP expression in cell culture was also observed with a

FluorImager SI (Molecular Dynamics, Sunnyvale, CA, USA) using a 515-nm emission
spectrum at PMT settings of 800. Images were processed and recorded with

ImageQuaNT software (Molecular Dynamics).

AP Staining and Activity Analysis

AP Staining Histochemical staining for ALP activity was performed using a
commercially available kit (86-R Alkaline Phosphatase; Sigma Diagnostics, Inc., St.
Louis, MO, USA) according to the manufacturer’s instructions. Mineralization was
evaluated using modified von Kossa silver nitrate staining method: cells were fixed for
10 minutes in 2% paraformaldehyde in 0.1 M of sodium cacodylate, pretreated for 20
minutes with saturated lithium carbonate solution, and washed in deionized water. The

plates were incubated with 5% silver nitrate solution for 30 minutes under a bright light,
washed with water, and treated with a 5% sodium thiosulphate solution for 2-3 minutes
followed by washing with water and air-drying.
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AP Activi_ty Analysis Cells were lysed using 0.04M Tris, lmM EDTA, and
0.15M NaC1, then resuspended in 10mM Tris and 0.1% Triton x-100. The ;uspension
was subjected to three freeze-thaw cycles. The supematant was then assayed using p-

nitrophenyl phosphate as a substrate, and incubated at 37C. Alkaline phosphatase
activity was analyzed using the p-nitrophenol colorometric assay and read on a

DYNATech Microplate reader.

RESULTS

Alkaline Phosphatase /von Kossa Staining

Bone marrow stromal cells were maintained in culture for 21 days. At various
timepoims, the amount of alkaline phosphatase activity and mineralization were assessed.

On day 14, the alkaline phosphatase staining pattern, was similar in wells comaining bone
marrow stromal cells derived from transgenic mice and wild type mice, and there were no

mineralized colonies visualized by von Kossa staining (Fig. 2). On day 21, it appears that

the area visualized by AP staining is slightly larger in transgenic cultures, although more

developed and intense mineralized colonies were observed in wild-type cultures (Fig 2).
The increased AP staining in transgenic cultures is more evident on day 21 in another

experimem (Fig.3A,B). In that experiment, BMP-2, a known stimulator of osteoblast

differentiation, was added to some cultures(Fig 3C,D), resulting in a slight increase in AP
staining and a significant increase in number of mineralized nodules in both wild-type
and transgenic wells. The increase in the number of mineralized nodules due to BMP-2
was exaggerated in transgenic cultures compared to wild-type. The amount of alkaline

phosphatase activity was quantified per well, and it indeed showed nearly tripled activity
in transgenic marrow cells versus wild-type cells (Fig 4A). However, since our

preliminary studies (Fig 5) have indicated that cell cultures derived from transgenic mice
result in significantly higher cell counts compared to wild-type mice, we measured the
amount of protein in each well in order to calculate the relative alkaline phosphatase

activity per mg of protein, and thus the true level of cellular activity. The difference in
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levels of alkaline phosphatase activity comparing wild-type to transgenic marrow cells
was not found to be statistically significant in this case (Fig 4-B). As expected, there was
a significant increase in AP activity normalized to protein in wild-type marrow cells

exposed to BMP-2. However, transgenic cells did not show a significant increase in AP
activity/mg protein when exposed to BMP-2.

Expression of osteoblast markers

Using the bone marrow stromal cell culture, several osteoblast markers, including

OP, collagen type I, BSP, and OC, were assessed at day 7, 10, 14, 17, and 21 in order to
observe any differences in the pattern of differentiation of marrow cells. Expression of

collagen was observed early and was decreased in marrow cells from transgenic mice
compared to wild-type mice at all time points (Fig 6). The difference between transgenic
and wild-type mice became more pronounced at later time points. OC expression was

initially observed at later stages of differentiation with a dramatic increase in OC
expression between days 17 and 21 in wild-type mice. Transgenic mice showed reduced

OC expression at both time points. OP expression was observed at the first time point in
both wild-type and transgenic mice. However, OP expression showed a prolonged

depression at days 10 and 14, compared to only at day 10 in wild-type mice. The onset of

BSP expression in wild-type mice occurred at day 1 O, with a subsequem dramatic
increase at day 14, and a sustained level through day 21. However, while transgenic
marrow cells also showed the onset of BSP expression beginning at day 10, its initial

intensity was significantly less than wild-type marrow cells, and its subsequent increase

17
was less pronounced. However, similar levels of BSP expression were observed in both

wild-type and transgenic cultures by day 17.
BMP-2 was added to cell cultures in order to observe any difference in bone
differentiation markers at day 21 (Fig 7). In the presence of BMP-2, collagen expression
in transgenic marrow cultures increased significantly more than wild-type culture,

resulting in a similar level of expression. A similar pattem was observed for BSP, but in
this case the level of BSP expression was found to be mildly higher in transgenic mice

compared to wild-type when exposed to BMP-2. OC levels appear to be similarly
increased upon the addition of BMP-2 in both transgenic and wild-type mice thus

preserving their relationship of decreased OC expression in transgenic mice.

GFP expression
Col2.3-GFP expression in bone marrow stromal cell cultures was assessed at at

the same time points by fluorescence microscopy and fluoroimaging. GFP expression
was found to begin between 10-14 days in both transgenic and wild-type mouse (Fig. 8-

12). However, while the number of transgenic colonies exhibiting GFP expression was
mildly increased compared to wild-type mice, the intensity of GFP expressi.on in
transgenic cultures was significantly less than wild-type cultures at 14, 17, and 21 days.
When BMP-2 is added to cultures and analyzed for GFP expression at day 21, both

transgenic and wild-type cultures show significantly more GFP-expressing colonies

compared to controls, but the pattern between transgenic and wild-type cultures remains
(Fig 13-15). When carried out through day 28, this pattem cominues (Fig 17).
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To determine whether osteoblast differemiation was simply delayed in transgenic
mice, stromal cultures were maimained until day 28. In both transgenic and wild-type

cultures, the level of GFP expression increased. However, the GFP expression in
transgenic mice remained less than transgenic mice (Fig 17).

In order to correlate GFP expression with mineralization, we evaluated cultures at
21 days simultaneously for GFP, alkaline phosphatase activity, and Von Kossa staining.

In alkaline phosphatase staining,, mineralization appears as a white area within a pink
colony. Von Kossa stains mineralized nodules dark red. Although transgenic cultures
show the same number of GFP-expressing colonies with significantly less intense
fluorescence compared to wild-type cultures, both alkaline phosphatase and Von Kossa

staining indicated that transgenic cultures have more areas of mineralization but with less

developed mineralized nodules. Additionally, areas of mineralization without GFP
expression were observed in transgenic mice. The addition of BMP-2 to cultures caused
increased numbers and greater developmem of mineralized nodules in bothtransgenic

and wild-type cultures based on alkaline phosphatase and Von Kossa staining (Fig. 16).

However, while the number and intensity of GFP expressing colonies was significantly
increased by BMP-2 in wild-type mice, the transgenic mice exhibited an increase in

colony numbers but without an increase in GFP expression intensity.

DISCUSSION
There has been a recent intensification of interest in the potential role of C/EBP as
a critical regulator in osteogenesis. Studies have shown that C/EBP delta upregulates

insulin-like growth factor-1 production, which is known to regulate osteoblast growth and

differentiation[22, 23]. Additionally, it has been found that C/EBP factors regulate COX2 and the (z-1 subunit of type I collagen in osteoblasts[25, 26]. Furthermore, Gutierrez et

al have shown that C/EBP and Runx2 factors interact synergistically to dramatically

enhance the bone-specific OC transcription in cell culture systems[27]. However, the
exact mechanisms whereby C/EBP factors regulate osteogenesis are still poorly

understood.

In order to better understand the role of C/EBP in osteogenesis, we used a
recently develop transgenic strain that overexpresses a dominant negative isoform of
C/EBP in order to inhibit the activity of endogenous C/EBP. C/EBPc knockout mice

have been generated, but these mice show perinatal lethality due to the impaired glycogen

synthesis, failure to store hepatic glycogen, failure to accumulate lipids in hepatocytes
and adipocytes, and the inability of effectively utilize brown adipose tissue. Thus, C/EBP

plays a crucial role in energy homeostasis in the neonatal period [10]. C/EBP[ and delta
knockout mice have also been developed, and they too display a high neonatal mortality
rate which is likely caused by inhibited thermogenesis, since they display no glycogen

abnormalities[6]. Our transgenic model avoids these problems by targeting, the transgene
to a limited tissue distribution. The pOBCol3.6 construct that is used in these transgenic

mice limits tissue expression by utilizing the Co13.6 fragmem of the Collal promoter,
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which is preferentially expressed in bone, teeth, skin, tendon, and lung. An alternative

construct with the Co12.3 promoter has been shown to have a more restricted pattern of

expression targeting bone even more specifically[43]. However, the Co13.6 construct
was preferred in our study because it has a broader expression in the osteoblast lineage,

while Co12.3 expression is restricted to osteocytes and mature osteoblasts.

From our data, it is evident that our transgenic mice exhibit impaired osteogenesis
consistent with the osteopenic phenotype exhibited osteopenia in this transgenic mouse

model. However, the nature of osteogenic impairment is not known. The pattern of bone
marker expression in our experiments suggests that there is a depressed and delayed
differentiation of osteoblasts from the transgenic mouse stromal cells compared to their

wild-type littermates. In our preliminary studies, we found that the number of transgenic
marrow stromal and calvarial cells in culture has been found to be significantly higher

than wild-type in the later stages of differemiation. Furthermore, we found significantly
more marrow cell colonies from transgenic mice in the alkaline phosphatase and GFP in

the later stages. One possibility is that the lack of functional C/EBP in the transgenic
mice causes a delay in osteoblast differentiation involving the earlier stages, causing the

cells to remain in the early proliferative stages for a longer period of time, resulting in a

greater accumulation of immature osteoblasts. This theory is supported by he prolonged

"valley’, seen in the Northern blotting of OP transcription (Fig. 6). Whether all stages of
differentiation are prolonged versus a specific segment is unclear from our data. The

pattern of diminished collagen and GFP expression in transgenic mice at all time points
with apparently increased numbers of GFP expressing cells is also consistent with this

theory. Essentially, at any one time point, the transgenic cultures contain a population of
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less mature osteoblasts compared to the wild-type cultures. Altematively, it is possible

that differentiation is delayed or prevented by cells showing enhanced or prolonged
proliferation.
The pattern of expression of BSP and alkaline phosphatase do not apparently fit
the theory of prolonged stages of differentiation. In some experimems, the expression of

BSP was greater in transgenic mice on day 17 and/or day 21 compared to wild-type,
especially in the presence of BMP-2 stimulation. However, higher levels of BSP may be
seen in transgenic mice due to accumulation of less differentiated osteoblasts. Alkaline

phosphatase showed increased staining on days 14 and 21. However, when the alkaline

phosphatase activity in transgenic mice was measured per milligram of protein, there was
not a statistically significant difference. Alkaline phosphatase activity is known to

increase during the earlier stages of differentiation then decreases when mineralization is

well progressed, having a peak around days 15-18 [31, 38]. Although the amount of

staining at days 14 and 21 were similar, this could be accounted for by the known peak in
activity in between.

As BMP-2 is known to stimulate osteoblast differentiation and promote bone
formation, we wanted to determine whether it can overcome the inhibitory effects of the

p20C/EBP[ transgene on osteoblast differemiation. We found that it does indeed
increase cell numbers and osteoblast marker expression (collagen, BSP, and OC),

resulting in a greater area of mineralization and more developed mineralized nodules.

However, osteoblast differentiation and bone mineralization is not restored to wild-type
levels. Therefore, BMP-2 seems to only partially overcome the p20C/EBP’[ transgene.
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In our attempt to correlate GFP expression with bone mineralization, we obtained
unexpected results. We found that mineralization in transgenic mice occurred in
significant amounts but in the absence of GFP expression within the corresponding
mineralized nodule at 21 days. In our other studies of bone differentiation markers,

collagen and OC expression is also significantly decreased at 21 days compared to wild-

type mice. Assuming that the bone differentiation marker pattern is preserved in
transgenic mice, this would suggest that osteoblasts from transgenic mice are less
differentiated, but apparemly without impaired mineralization ability. This could
possibly be the net effect of a significantly larger cell population consisting of less mature
osteoblasts that individually have impaired mineralization ability. Alternatively, the

transgene may somehow be altering the mechanism of osteoblastic mineralization, for

example, via regulation of OC expression since OC may be an inhibitor of
mineralization.

In light of this collective data, the exact nature of the delay in osteoblast
differentiation seen in transgenic mice is still unclear. Up through day 28, the data

suggests that the progression of osteoblast differentiation in transgenic mice is

significantly behind wild-type mice. The initial delay in transgenic mice appears to be at
least several days behind wild-type mice. However, the eventual outcome of this
osteoblastic differentiation could follow one of several potential patterns. The simplest

effect of the transgene is to effectively delay only a portion or the entire course of

differemiation, such that after a prolonged time course, the osteoblasts would eventually
become mature osteocytes. If this were the case, one might expect the osteopenic

phenotype of the transgenic mice to eventually resolve late in their life. However,
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preliminary studies show that the degree of osteopenia remains constant through 10
months of age, suggesting that the effect of the transgene is more complex. Extending
stromal cell cultures until senescence is reached and observing the degree of osteopenia
in transgenic mice at very late time points may clarify this matter. The duration of the

prolongation of differentiation may be identified by assessing the rate of differentiation of
wild-type mice at multiple stages, and to then compare it to the rate of differentiation of
transgenic mice at the corresponding stages. Another potential differentiation pattern is

delayed differentiation but without eventual differentiation of osteoblasts into fully
mature osteocytes. The bone mineralization studies demonstrated that less-mature

osteoblasts can still mineralize in significant quantities. If this were the case, transgenic
mice would remain osteopenic throughout its entire life span, and their osteoblast cultures

would never fully express the bone markers of late differentiation.

CONCLUSION

In our experiments, we demonstrated that the markers for osteoblast
differemiation have a depressed and delayed pattem of expression in the bone marrow

stromal cells derived from transgenic mice compared to wild-type mice. This pattern

suggests that the inhibition of functional C/EBP prolongs the proliferative stage of
differentiation, and possibly effects later stages (Fig. 18). The resulting effect is delayed
osteoblast differemiation, a higher cell count, but with sustained mineralization ability.

In order to fully understand the role of C/EBP in bone differentiation and mineralization,
further in vitro studies need to be conducted over a longer time frame with corresponding
in vivo experiments.
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Figure 1 The molecular structure of C/EBP mRNA. There are two AUG start codons
in this diagram, which represent the starting points for translation of the P33C/EBP (LAP)
and P20C/EBP (LIP) isoforms. The p20C/EBP isoform is the truncated form, acting as a
dominant negative regulator of C/EBP function.

Figure 2 Alkaline phosphatase staining and von Kossa staining. Bone marrow
stromal cells were maintained in culture then stained for alkaline phosphatase activity and
mineralization simultaneously. Each experiment was performed in triplicate wells. A)
Wild-type at day 14. B) Transgenic at day 14. C) Wild-type at day 21. D) Transgenic at
day 21. Pink staining represents alkaline phosphatase staining. Dark purple staining
represents mineralized bone nodules by von Kossa staining.
Figure 3 Alkaline phosphatase staining and von Kossa staining in the presence of
BMP-2. Bone marrow stromal cells were maintained in culture with 30ug/ml of BMP-2
as an osteogenic stimulus, then stained for alkaline phosphatase activity and
mineralization simultaneously. Each experiment was performed in triplicate wells. A)
Wild-type at day 14. B) Transgenic at day 14. C) Wild-type at day 21. D) Transgenic at
day 21. Pink staining represents alkaline phosphatase staining. Dark purple staining
represents mineralized bone nodules by yon Kossa staining.

-ere

Figure 4 Alkaline phosphatase activity. Marrow stromal cell cultures
assayed
for alkaline phosphatase activity 21 days. Marrow stromal cells from wild-type and
transgenic mice were used. Some marrow cell cultures were treated with BMP-2. A) AP
activity measured per well. B) AP activity measured per milligram of protein. Error bars
represent standard error.

Figure 5 Calvarial cell proliferation. A set number of calvarial stromal cells were
placed in culture medium and allowed to proliferate. Cells were counted at multiple time
points, up to 21 days. Error bars represent standard deviation.
Figure 6 Northern blot analysis. Transcription of bone differentiation markers,
osteopontin, Collal, BSP, and osteocalcin, were assessed at multiple time points using
marrow stromal cells from wild-type and transgenic mice. The p20 Tag is an epitope that
was integrated into the p20C/EBP transgene and used here to confirm the presence of the
transgenic p20C/EBP. EtBr was used as a loading control.
Figure 7 Northern blot analysis in the presence of BMP-2. Transcription of bone
differentiation markers, Collal, BSP, and osteocalcin, were assessed at 21 days using
marrow stromal cells from wild-type and transgenic mice that were cultured with and
without the presence of BMP-2. Actin was used as a loading control.
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Figure 8 Fluorimaging of GFP expression. Expression of the bone differentiation
markers, GFP (associated with collagen expression) was photographed by fluorimaging
at multiple time points using marrow stromal cells from wild-type and transgenic mice.
Each experimem was performed in triplicate wells.
Figure 9 Visualization of GFP expression via fluorescent microscopy Day 10.
Expression of GFP was photographed by concatemerizing 25 fluorescent images at day
10 using marrow stromal cells from wild-type and transgenic mice. A) wild-type marrow
cells. B) transgenic marrow cells. C) wild-type marrow cells with BMP-2. D) transgenic
marrow cells with BMP-2.

Figure 10 Visualization of GFP expression via fluorescent microscopy Day 14.
Expression of GFP was photographed by concatemerizing 25 fluorescent images at day
14 using marrow stromal cells from wild-type and transgenic mice. A) wild-type marrow
cells. B) transgenic marrow cells. C) wild-type marrow cells with BMP-2. D) transgenic
marrow cells with BMP-2.
Figure 11 Visualization of GFP expression via fluorescent microscopy Day 17.
Expression of GFP was photographed by concatemerizing 25 fluorescent images at day
17 using marrow stromal cells from wild-type and transgenic mice. A) wild-type marrow
cells. B) transgenic marrow cells. C) wild-type marrow cells with BMP-2. D) transgenic
marrow cells with BMP-2.

Figure 12 Visualization of GFP expression via fluorescent microscopy Day 21.
Expression of GFP was photographed by concatemerizing 25 fluorescent images at day
21 using marrow stromal cells from wild-type and transgenic mice. A) wild-type marrow
cells. B) transgenic marrow cells. C) wild-type marrow cells with BMP-2. D) transgenic
marrow cells with BMP-2.

o

Figure 13 Fluorimaging of GFP expression with BMP-2. Expression GFP was
photographed by fluorimaging at 21 days using marrow stromal cells from wild-type and
transgenic mice with and without the presence of BMP-2. Each experiment was
performed in triplicate wells. A) wild-type marrow cells. B) transgenic marrow cells. C)
wild-type marrow cells with BMP-2. D) transgenic marrow cells with BMP-2.

Figure 14 Microscopy of cell culture colonies. Individual colonies from wild-type
and transgenic cell cultures were observed under fluorescem microscopy and brightfield
microscopy at 21 days. A) wild-type marrow cells under fluorescence microscopy. B)
transgenic marrow cells under fluorescence microscopy. C) wild-type marrow cells
under brightfield microscopy. D) transgenic cells under brightfield microscopy. Darker
areas in brightfield microscopy indicate mineralization.

28

Figure 15 Microscopy of cell culture colonies with BMP-2. Individual colonies from
wild-type and transgenic cell cultures treated with BMP-2 were observed under
fluorescent microscopy and brightfield microscopy at 21 days. A) wild-type marrow
cells under fluorescence microscopy. B) transgenic marrow cells under fluorescence
microscopy. C) wild-type marrow cells under brightfield microscopy. D) transgenic
cells under brightfield microscopy. Darker areas in brightfield microscopy indicate
mineralization.
Figure 16 Correlation of GFP expression with mineralization. In order to determine
whether GFP expression is proportional to mineralization, marrow cell cultures from
wild-type and transgenic mice were photographed with the fluorimager at day 21 to
visualize GFP expression, then subsequently underwent alkaline phosphatase and von
Kossa staining to visualize mineralization. A) fluorimaging. B) AP staining C) AP
staining with von Kossa staining.

Figure 17 Extended visualization of GFP expression via fluorescent microscopy
In order to determine whether GFP expression in transgenic marrow cells
catch
eventually
up with wild-type expression, the culture duration was extended and the
cultures were treated with BMP-2. Expression of GFP was photographed by
concatemerizing 25 fluorescent images at day 17 using marrow stromal cells from wildtype and transgenic mice. A) wild-type marrow cells at 22 days B) transgenic marrow
cells at 22 days. C) wild-type marrow cells at 24 days. D) transgenic marrow cells at 24
days. E) wild-type marrow cells at 28 days. B) transgenic marrow cells at 8 days.
with BMP-2.

Figure 18 Diagram of theorized osteoblast differentiation pattern. The bone marker
expression on cultured marrow cells derived from transgenic mice suggests that the early
proliferative stage of differentiation is prolonged. The nature of the later stages of
differemiation cannot be determined based on our data.
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